- Home
- VALN vs ETON Comparison
VALN vs ETON Comparison
Compare VALN & ETON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VALN
- ETON
- Stock Information
- Founded
- VALN 2012
- ETON 2017
- Country
- VALN France
- ETON United States
- Employees
- VALN N/A
- ETON N/A
- Industry
- VALN Biotechnology: Biological Products (No Diagnostic Substances)
- ETON Biotechnology: Pharmaceutical Preparations
- Sector
- VALN Health Care
- ETON Health Care
- Exchange
- VALN Nasdaq
- ETON Nasdaq
- Market Cap
- VALN N/A
- ETON 329.8M
- IPO Year
- VALN 2021
- ETON 2018
- Fundamental
- Price
- VALN $6.97
- ETON $12.50
- Analyst Decision
- VALN Strong Buy
- ETON Strong Buy
- Analyst Count
- VALN 2
- ETON 3
- Target Price
- VALN $16.00
- ETON $27.67
- AVG Volume (30 Days)
- VALN 19.0K
- ETON 222.5K
- Earning Date
- VALN 05-06-2025
- ETON 05-08-2025
- Dividend Yield
- VALN N/A
- ETON N/A
- EPS Growth
- VALN N/A
- ETON N/A
- EPS
- VALN N/A
- ETON N/A
- Revenue
- VALN $175,564,758.00
- ETON $39,011,000.00
- Revenue This Year
- VALN $19.17
- ETON $92.33
- Revenue Next Year
- VALN $26.31
- ETON $52.62
- P/E Ratio
- VALN N/A
- ETON N/A
- Revenue Growth
- VALN 10.32
- ETON 23.29
- 52 Week Low
- VALN $3.62
- ETON $3.03
- 52 Week High
- VALN $9.50
- ETON $18.41
- Technical
- Relative Strength Index (RSI)
- VALN 50.65
- ETON 36.53
- Support Level
- VALN $6.70
- ETON $12.24
- Resistance Level
- VALN $7.38
- ETON $13.46
- Average True Range (ATR)
- VALN 0.31
- ETON 0.94
- MACD
- VALN -0.05
- ETON -0.15
- Stochastic Oscillator
- VALN 25.47
- ETON 10.03
About ETON Eton Pharmaceuticals Inc.
Eton Pharmaceuticals Inc is a United States based specialty pharmaceutical company. The company is engaged in developing and commercializing pharmaceutical products to fulfill an unmet patient need. It has four commercial rare disease products, Alkindi Sprinkle for the treatment of adrenocortical insufficiency; Carglumic Acid for the treatment of hyperammonemia, Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of hereditary tyrosinemia type 1 (HT-1). The Company has three additional product candidates in late-stage development: ET-400, ET-600, and ZENEO hydrocortisone autoinjector.